BioPorto Diagnostics A/S
Grusbakken 8
Gentofte
DK-2820
Tel: 1-45-4529-0000
Fax: 1-45-4529-0001
Website: http://www.bioporto.com/
30 articles about BioPorto Diagnostics A/S
-
BioPorto adds Mr. Nis Kruse as EVP of Strategic Partnerships and GM of EMEA & APAC
12/5/2022
BioPorto A/S announced that Mr. Nis Kruse joined the Company as EVP of Strategic Partnerships and General Manager of EMEA & APAC.
-
BioPorto Announces Interim Results for the First Nine Months of 2022
11/9/2022
BioPorto A/S announced interim financial results for the first nine months of 2022 and business progress for the third quarter of 2022.
-
BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call - November 03, 2022
11/3/2022
BioPorto A/S announced that in connection with the release of its Interim Report for the third quarter of 2022, the Company’s management team will host an online investor presentation on November 9, 2022 at 14:00 Central European Time / 8:00 Eastern Time via HC Andersen Capital.
-
BioPorto Announces Interim Results for the First Six Months of 2022
8/17/2022
BioPorto A/S announced interim financial results for the first six months of 2022 and business progress for the second quarter of 2022.
-
BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call - Aug 08, 2022
8/8/2022
BioPorto A/S announced that in connection with the release of its Interim Report for the second quarter of 2022, the Company’s management team will host an online investor presentation on August 17, 2022 at 14:00 Central European Time / 8:00 Eastern Time via HC Andersen Capital.
-
BioPorto Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S.
6/28/2022
BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced its achievement of targeted subject enrollment for the third part of a 3-part clinical study to support a U.S. Food and Drug Administration (FDA) De Novo submission for use of The NGAL Test in identifying patients under the age of 22 at risk for Acute Kidney Injury (AKI).
-
There were multiple leadership changes in the biopharma industry, with several new chief executive officers tapped to guide companies through their next growth phases.
-
Moderated Webcast with BioPorto’s Management
6/21/2022
BioPorto A/S provided details of a previously announced session with members of its management team.
-
BioPorto Appoints World Leading Expert and Pioneer on the Clinical Utility of the NGAL Biomarker, Dr. Prasad Devarajan, MD FAAP FASN, as New Senior Medical Director
6/20/2022
BioPorto A/S announced the appointment of Dr. Prasad Devarajan, MD FAAP FASN, as Senior Medical Director effective July 1, 2022.
-
BioPorto: Changes in the Board of Directors - Jan. 16, 2018
1/16/2018
The company will nominate Britt Meelby Jensen for election as a new Board member at BioPorto’s Annual General Meeting on April 13, 2018.
-
BioPorto: Changes in the Board of Directors - Jan. 4, 2018
1/4/2018
Board member Niels Christian Nielsen will not be seeking re-election at BioPorto’s Annual General Meeting on April 13, 2018.
-
BioPorto: Financial Calendar 2018
12/11/2017
A look at BioPorto's financial calendar for 2018.
-
USPTO Approves Bioporto's NGAL Trauma Patent for Issuance
11/10/2017
BioPortos’ issued patents in the U.S. now comprises BioPorto’s NGAL Ratio patent and issued NGAL patent in-licensed from The Trustees of Columbia University. I
-
BioPorto: Interim Report, Third Quarter of 2017
11/7/2017
BioPorto is currently conducting a clinical study to get The NGAL Test™ for diagnosis of Acute Kidney Injury approved in the USA.
-
BioPorto: Private Placement Fully Subscribed
11/2/2017
The board decided on October 27, 2017 to partially exercise the authorization in article 16b of the Company’s Articles of Association to issue up to 13,015,625 new shares in a private placement to a limited number of investors.
-
BioPorto Release: Interim Report, Second Quarter Of 2017
8/10/2017
-
BioPorto Release: Strong Data From Previous NGAL Study Provides The Basis For New Protocol And FDA Registration Application
7/14/2017
-
BioPorto Release: NGAL Demonstrates Positive Economic Outcomes: Greatly Reduces Costs Associated With Diagnosis And Treatment Of Acute Kidney Injury
6/7/2017
-
BioPorto Release: First Patient Recruited For The NGAL Test Clinical Study In The US.
4/12/2017
-
Clinical Leaders Reinforce Belief In NGAL For Detection Of AKI Following FDA's Decision On BioPorto's The NGAL Test
6/6/2016